Cargando…
Predictors of serious adverse events and non‐response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid
BACKGROUND & AIMS: Obeticholic acid (OCA) has recently been restricted in patients with primary biliary cholangitis (PBC) with “advanced cirrhosis” because of its narrow therapeutic index. We aimed to better define the predicting factors of hepatic serious adverse events (SAEs) and non‐response...
Ejemplares similares
-
Real-world experience with obeticholic acid in patients with primary biliary cholangitis
por: D’Amato, Daphne, et al.
Publicado: (2021) -
High prevalence of lower limb atherosclerosis is linked with the gut–liver axis in patients with primary biliary cholangitis
por: Ponziani, Francesca Romana, et al.
Publicado: (2022) -
The renin‐angiotensin‐aldosterone system, neurohumoral axis and cardiovascular mortality in LURIC
por: Yazdani, Babak, et al.
Publicado: (2022) -
Impact on follow‐up strategies in patients with primary sclerosing cholangitis
por: Bergquist, Annika, et al.
Publicado: (2022) -
Coronavirus Disease 2019 in Autoimmune Hepatitis: A Lesson From Immunosuppressed Patients
por: Gerussi, Alessio, et al.
Publicado: (2020)